Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
← catalyst calendarNCT07221331 · readout in 42 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
9
Country
Egypt
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-19 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neurofibromatosis Type 1
Primary outcome
what the primary-completion date above is the date OFPrevalence of patients with Neurofibromatosis type 1-Plexiform Neurofibromas
measured 13 Years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed